For the 192,000 men diagnosed with prostate cancer last year, Dr. Mitch Gold's Seattle-based BioTech company Dendreon may hold the key to their survival. The Food and Drug Administration last April finally approved Provenge, a prostate cancer vaccine that stimulates the body's own immune system to attack tumors. In one clinical trial, Provenge extended the lives of patients with prostate cancer on average by 4.1 months, with 32% of patients still alive three years after treatment. While Gold and Dendreon stand to benefit -- it's estimated Provenge could generate more than $1 billion in U.S. sales -- ultimately the real beneficiaries will be the patients themselves. --J.P.M.
NEXT: CEO runner-up: Jack Ma
Last updated July 09 2010: 1:19 PM ET